Molecular pathways: Targeting death receptors and Smac mimetics

Clinical Cancer Research

Volumn 20, Issue 15, 2014, Pages 3915-3920

  Fulda, Simone ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIRINAPANT; CASPASE 3; CASPASE 8; DEATH RECEPTOR; DROZITUMAB; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FAS LIGAND; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEXATUMUMAB; MAPATUMUMAB; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE MIMETIC; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE MIMETIC AEG40730; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE MIMETIC BV6; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE MIMETIC LBW242; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE MIMETIC SM 164; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS; BIOMIMETIC MATERIAL; DIABLO PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; MITOCHONDRIAL PROTEIN; OLIGOPEPTIDE; SIGNAL PEPTIDE; SMAC PEPTIDE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL STUDY; DIGESTIVE SYSTEM CANCER; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG TARGETING; DRUG TOLERABILITY; ENZYME ACTIVATION; GLIOBLASTOMA; GYNECOLOGIC CANCER; HEMATOLOGIC MALIGNANCY; HUMAN; MOLECULAR DYNAMICS; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PANCREAS CARCINOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; TRANSLATIONAL RESEARCH; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; METABOLISM; NEOPLASMS; PATHOLOGY; PROGNOSIS;

ANTINEOPLASTIC AGENTS; BIOMIMETIC MATERIALS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MITOCHONDRIAL PROTEINS; MOLECULAR TARGETED THERAPY; NEOPLASMS; OLIGOPEPTIDES; PROGNOSIS; RECEPTORS, DEATH DOMAIN; SIGNAL TRANSDUCTION;

EID: 84905441719     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-2376     Document Type: Article

References (58)

1. Fulda S. Tumor resistance to apoptosis. Int J Cancer 2009;124:511-5.
2. Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006;25:4798-811.
3. Fulda S, Vucic D. Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov 2012;11:109-24.
4. Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, Garg P, et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 2007;131:669-81.
5. Vince JE, Wong WW, Khan N, Feltham R, Chau D, Ahmed AU, et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 2007;131:682-93.
6. Petersen SL, Wang L, Yalcin-Chin A, Li L, Peyton M, Minna J, et al. Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell 2007;12:445-56.
7. Bertrand MJ, Milutinovic S, Dickson KM, Ho WC, Boudreault A, Durkin J, et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell 2008;30:689-700.
8. Oeckinghaus A, Hayden MS, Ghosh S. Crosstalk in NF-kappaB signaling pathways. Nat Immunol 2011;12:695-708.
9. Wang L, Du F, Wang X. TNF-alpha induces two distinct caspase-8 activation pathways. Cell 2008;133:693-703.
10. Eckhardt I, Roesler S, Fulda S. Identification of DR5 as a critical, NF-kappaB-regulated mediator of Smac-induced apoptosis. Cell Death Dis 2013;4:e936.
11. Beug ST, Cheung HH, Lacasse EC, Korneluk RG. Modulation of immune signalling by inhibitors of apoptosis. Trends Immunol 2012;33:535-45.
12. Fulda S. Regulation of cell migration, invasion and metastasis by IAP proteins and their antagonists. Oncogene 2014;33:671-6.
13. Cheung HH, Mahoney DJ, Lacasse EC, Korneluk RG. Down-regulation of c-FLIP Enhances death of cancer cells by smac mimetic compound. Cancer Res 2009;69:7729-38.
14. Fakler M, Loeder S, Vogler M, Schneider K, Jeremias I, Debatin KM, et al. Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance. Blood 2009;113:1710-22.
15. Vogler M, Walczak H, Stadel D, Haas TL, Genze F, Jovanovic M, et al. Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma. Cancer Res 2009;69:2425-34.
16. Loeder S, Fakler M, Schoeneberger H, Cristofanon S, Leibacher J, Vanlangenakker N, et al. RIP1 is required for IAP inhibitor-mediated sensitization of childhood acute leukemia cells to chemotherapyinduced apoptosis. Leukemia 2012;26:1020-9.
17. Vellanki SH, Grabrucker A, Liebau S, Proepper C, Eramo A, Braun V, et al. Small-molecule XIAP inhibitors enhance gamma-irradiationinduced apoptosis in glioblastoma. Neoplasia 2009;11:743-52.
18. Fulda S, Wick W, Weller M, Debatin KM. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 2002;8:808-15.
19. Li L, Thomas RM, Suzuki H, De Brabander JK, Wang X, Harran PG. A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death. Science 2004;305:1471-4.
20. Wang G, Wang X, Yu H, Wei S, Williams N, Holmes DL, et al. Smallmolecule activation of the TRAIL receptor DR5 in human cancer cells. Nat Chem Biol 2013;9:84-9.
21. Loeder S, Zenz T, Schnaiter A, Mertens D, Winkler D, Dohner H, et al. A novel paradigm to trigger apoptosis in chronic lymphocytic leukemia. Cancer Res 2009;69:8977-86.
22. Frenzel LP, Patz M, Pallasch CP, Brinker R, Claasen J, Schulz A, et al. Novel X-linked inhibitor of apoptosis inhibiting compound as sensitizer for TRAIL-mediated apoptosis in chronic lymphocytic leukaemia with poor prognosis. Br J Haematol 2011;152:191-200.
23. Servida F, Lecis D, Scavullo C, Drago C, Seneci P, Carlo-Stella C, et al. Novel second mitochondria-derived activator of caspases (Smac) mimetic compounds sensitize human leukemic cell lines to conventional chemotherapeutic drug-induced and death receptor-mediated apoptosis. Invest New Drugs 2011;29:1264-75.
24. Guo F, Nimmanapalli R, Paranawithana S, Wittman S, Griffin D, Bali P, et al. Ectopic overexpression of second mitochondria-derived activator of caspases (Smac/DIABLO) or cotreatment with N-terminus of Smac/DIABLO peptide potentiates epothilone B derivative-(BMS 247550) and Apo-2L/TRAIL-induced apoptosis. Blood 2002;99:3419-26.
25. Chauhan D, Neri P, Velankar M, Podar K, Hideshima T, Fulciniti M, et al. Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). Blood 2007;109:1220-7.
26. Stadel D, Mohr A, Ref C, MacFarlane M, Zhou S, Humphreys R, et al. TRAIL-induced apoptosis is preferentially mediated via TRAIL receptor 1 in pancreatic carcinoma cells and profoundly enhanced by XIAP inhibitors. Clin Cancer Res 2010;16:5734-49.
27. Mori T, Doi R, Kida A, Nagai K, Kami K, Ito D, et al. Effect of the XIAP inhibitor Embelin on TRAIL-induced apoptosis of pancreatic cancer cells. J Surg Res 2007;142:281-6.
28. Zhou W, Shi J, Niu Z, Luo H, Tian H, Gao J, et al. SmacN7 enhances the sensitivity of pancreatic cancer cells to tumor necrosis factorrelated apoptosis-inducing ligand or gemcitabine. Oncol Lett 2013;5:1760-4.
29. Lu J, McEachern D, Sun H, Bai L, Peng Y, Qiu S, et al. Therapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatment. Mol Cancer Ther 2011;10:902-14.
30. Varfolomeev E, Alicke B, Elliott JM, Zobel K, West K, Wong H, et al. X chromosome-linked inhibitor of apoptosis regulates cell death induction by proapoptotic receptor agonists. J Biol Chem 2009;284:34553-60.
31. Gillissen B, Richter A, Richter A, Overkamp T, Essmann F, Hemmati PG, et al. Targeted therapy of the XIAP/proteasome pathway overcomes TRAIL-resistance in carcinoma by switching apoptosis signaling to a Bax/Bak-independent 'type I' mode. Cell Death Dis 2013;4:e643.
32. Zhang S, Li G, Zhao Y, Liu G, Wang Y, Ma X, et al. Smac mimetic SM-164 potentiates APO2L/TRAIL- and doxorubicin-mediated anticancer activity in human hepatocellular carcinoma cells. PLoS One 2012;7:e51461.
33. Fingas CD, Blechacz BR, Smoot RL, Guicciardi ME, Mott J, Bronk SF, et al. A smac mimetic reduces TNF related apoptosis inducing ligand (TRAIL)-induced invasion and metastasis of cholangiocarcinoma cells. Hepatology 2010;52:550-61.
34. Amm HM, Zhou T, Steg AD, Kuo H, Li Y, Buchsbaum DJ. Mechanisms of drug sensitization to TRA-8, an agonistic death receptor 5 antibody, involve modulation of the intrinsic apoptotic pathway in human breast cancer cells. Mol Cancer Res 2011;9:403-17.
35. Bockbrader KM, Tan M, Sun Y. A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL- and etoposideinduced apoptosis in breast cancer cells. Oncogene 2005;24:7381-8.
36. Fandy TE, Shankar S, Srivastava RK. Smac/DIABLO enhances the therapeutic potential of chemotherapeutic drugs and irradiation, and sensitizes TRAIL-resistant breast cancer cells. Mol Cancer 2008;7:60.
37. Petrucci E, Pasquini L, Petronelli A, Saulle E, Mariani G, Riccioni R, et al. A small molecule Smac mimic potentiates TRAIL-mediated cell death of ovarian cancer cells. Gynecol Oncol 2007;105:481-92.
38. Petrucci E, Pasquini L, Bernabei M, Saulle E, Biffoni M, Accarpio F, et al. A small molecule SMAC mimic LBW242 potentiates TRAIL- and anticancer drug-mediated cell death of ovarian cancer cells. PLoS One 2012;7:e35073.
39. Mao HL, Pang Y, Zhang X, Yang F, Zheng J, Wang Y, et al. Smac peptide potentiates TRAIL- or paclitaxel-mediated ovarian cancer cell death in vitro and in vivo. Oncol Rep 2013;29:515-22.
40. Gatti L, De Cesare M, Ciusani E, Corna E, Arrighetti N, Cominetti D, et al. Antitumor activity of a novel homodimeric SMAC mimetic in ovarian carcinoma. Mol Pharm 2014;11:283-93.
41. Abhari BA, Cristofanon S, Kappler R, Von Schweinitz D, Humphreys R, Fulda S. RIP1 is required for IAP inhibitor-mediated sensitization for TRAIL-induced apoptosis via a RIP1/FADD/caspase-8 cell death complex. Oncogene 2013;32:3263-73.
42. Basit F, Humphreys R, Fulda S. RIP1 Protein-dependent assembly of a cytosolic cell death complex is required for inhibitor of apoptosis (IAP) inhibitor-mediated sensitization to lexatumumab-induced apoptosis. J Biol Chem 2012;287:38767-77.
43. Lecis D, Drago C, Manzoni L, Seneci P, Scolastico C, Mastrangelo E, et al. Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and bortezomib. Br J Cancer 2010;102:1707-16.
44. Ren X, Xu Z, Myers JN, Wu X. Bypass NFkappaB-mediated survival pathways by TRAIL and Smac. Cancer Biol Ther 2007;6:1031-5.
45. Metwalli AR, Khanbolooki S, Jinesh G, Sundi D, Shah JB, Shrader M, et al. Smac mimetic reverses resistance to TRAIL and chemotherapy in human urothelial cancer cells. Cancer Biol Ther 2010;10:885-92.
46. Wu MS, Wang GF, Zhao ZQ, Liang Y, Wang HB, Wu MY, et al. Smac mimetics in combination with TRAIL selectively target cancer stem cells in nasopharyngeal carcinoma. Mol Cancer Ther 2013;12:1728-37.
47. Loeder S, Drensek A, Jeremias I, Debatin KM, Fulda S. Small molecule XIAP inhibitors sensitize childhood acute leukemia cells for CD95-induced apoptosis. Int J Cancer 2010;126:2216-28.
48. Laukens B, Jennewein C, Schenk B, Vanlangenakker N, Schier A, Cristofanon S, et al. Smac mimetic bypasses apoptosis resistance in FADD- or Caspase-8-deficient cells by priming for tumor necrosis factor alpha-induced necroptosis. Neoplasia 2011;13:971-9.
49. Geserick P, Hupe M, Moulin M, Wong WW, Feoktistova M, Kellert B, et al. Cellular IAPs inhibit a cryptic CD95-induced cell death by limiting RIP1 kinase recruitment. J Cell Biol 2009;187:1037-54.
50. Kater AP, Dicker F, Mangiola M, Welsh K, Houghten R, Ostresh J, et al. Inhibitors of XIAP sensitize CD40-activated chronic lymphocytic leukemia cells to CD95-mediated apoptosis. Blood 2005;106:1742-8.
51. Krepler C, Chunduru SK, Halloran MB, He X, Xiao M, Vultur A, et al. The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells. Clin Cancer Res 2013;19:1784-94.
52. Smith MA, Carol H, Evans K, Richmond J, Kang M, Reynolds CP, et al. Birinapant (TL32711), a small molecule smac mimetic, induces regressionsin childhood acute lymphoblastic leukemia (ALL) xenografts that express TNF{alpha} and synergizes with TNF{alpha} in vitro - a report from the Pediatric Preclinical Testing Program (PPTP). ASH Annu Meet Abstr 2012;120:3565.
53. He S, Wang L, Miao L, Wang T, Du F, Zhao L, et al. Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. Cell 2009;137:1100-11.
54. Vanlangenakker N, Vanden Berghe T, Bogaert P, Laukens B, Zobel K, Deshayes K, et al. cIAP1 and TAK1 protect cells from TNF-induced necrosis by preventing RIP1/RIP3-dependent reactive oxygen species production. Cell Death Differ 2011;18:656-65.
55. Amaravadi RK, Schilder RJ, Dy GK, Ma WW, Fetterly GJ, Weng DE, et al. Phase I study of the Smac mimetic TL32711 in adult subjects with advanced solid tumors & lymphoma to evaluate safety, pharmocokinetics, pharmocodynamics and anti-tumor activity. In: Proceedings of the 102nd Annual Meeting of the American Association of Cancer Research; 2011 Apr. 2-6; Orlando, Florida: AACR. nr LB-406.
56. Infante JR, Dees EC, Burris HA, Zawel L, Sager JA, Stevenson C, et al. A phase I study of LCL-161, an oral inhibitor, in patients with advanced cancer. In: Proceedings of the 100th Annual Meeting of the American Association for Cancer Research; 2010 Apr. 17-21; Washington, DC, PA: AACR. nr 2775.
57. Sikic BI, Eckhardt SG, Gallant G, Burris HA, Camidge DR, Covelas AD, et al. Safety, pharmocokinetics (PK), and pharmacodynamics (PD) of HGS1029, an inhibitor of apoptosis protein (IAP), in patients (Pts.) with advanced solid tumors: results of a phase I study. J Clin Oncol 29:2011(suppl; abstr 3008).
58. Ndubaku C, Varfolomeev E, Wang L, Zobel K, Lau K, Elliott LO, et al. Antagonism of c-IAP and XIAP proteins is required for efficient induction of cell death by small-molecule IAP antagonists. ACS Chem Biol 2009;4:557-66.